Target intelligence / Profile preview

PSMD3 antisense RNA 1 (PSMD3-AS1)

Target
PSMD3-AS1
Molecular classification
Long noncoding RNA (lncRNA), Antisense RNA
01

Overview

PSMD3 antisense RNA 1 (PSMD3-AS1) is a long noncoding antisense RNA transcribed from the opposite strand of the PSMD3 gene locus. Antisense RNAs, including PSMD3-AS1, are typically involved in gene expression regulation by base pairing with their cognate protein-coding mRNAs[3][6]. PSMD3-AS1 has recently been associated with diagnostic utility in diseases such as atherosclerotic renal artery stenosis[4]. Its precise biological functions and disease implications are under investigation, but as with other antisense lncRNAs, its regulatory potential makes it a candidate for future therapeutic or biomarker development[4][6].\n\nNo evidence currently links PSMD3-AS1 to specific drugs, mechanisms of action, or major safety concerns. Most available information is about its sequence, classification, genomic context, and initial disease association as a candidate biomarker.

Other names
PR11-387H17.6RP11-387H17.6PSMD3-AS1
02

Mechanism of action

Not applicable—no drugs currently listed for this target; lncRNAs often act through RNA–RNA interactions or modulation of gene expression

03

Biological functions

Gene expression regulation (through antisense interaction)Potential involvement in cell signaling and disease pathways (as biomarker/regulator)
04

Disease associations

Cardiovascular disease: identified as potential biomarker for atherosclerotic renal artery stenosisOther: relevance in molecular diagnostics is being explored; broader disease associations not yet clearly established
05

Safety considerations

None reported; as a noncoding RNA, therapeutic or diagnostic use would require evaluation for off-target effects and delivery challenges
06

Biomarkers

Considered a potential biomarker for atherosclerotic renal artery stenosis

Beyond the preview

Go deeper on PSMD3 antisense RNA 1 (PSMD3-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSMD3 antisense RNA 1 (PSMD3-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call